调肝理脾方抑制酒精性肝纤维化的实验研究

Experimental research on inhibiting action of Tiaoganlipi prescription on alcohol hepatic fibrosis

[目的]探讨调肝理脾方对实验性酒精性肝纤维化大鼠的抑制作用及其机制。[方法]Wistar雄性大鼠以"白酒-吡唑-玉米油"混合液灌胃16周制备酒精性肝纤维化大鼠模型,给药后检测肝功能、肝组织病理学变化、肝组织中转化生长因子-β1(TGF-β1)蛋白表达。[结果]酒精性肝纤维化模型大鼠肝功能显著异常,肝纤维化明显;经4周治疗,与模型组比较,中药组及西药组血清中丙氨酸氨基转移酶、天冬氨酸转氨酶、透明质酸水平均有显著下降(P<0.01),且中药组能显著下调大鼠肝组织中TGF-β1蛋白。[结论]调肝理脾方能够有效阻止和逆转酒精性肝纤维化的进程。

[Objective]To probe into the inhibiting action of Tiaoganlipi prescription on alcohol hepatic fibrosis in rats and potential mechanism. [Methods]Wistar male rats were administered by intragastrical perfusion by some mixture of alcohol-Pyrazole-coil oil for sixteen weeks. And they were randomly assigned to three groups, a model control group, a Tiaoganlipi Prescription group, a positive control group. After four weeks＇ intervention,the variety of Hepatic function, liver tissue pathology and expression of TGF-β1 in liver tissue were observed. [Results]At the end of 16th week, the model rats＇ hepatic functions were changed and abnormal, and fibrosis was found in hepatic histopathology. When giving intervention for four weeks, HA, alanine aminotransferase（ALT）, aspartic aminotransferase （AST） decreased significantly （P 〈 0. 01） in rats blood serum of the Tiaoganlipi Prescription group, the positive control group compared with them of model group, and expression of TGF-β1 was depressed in Tiaoganlipi Prescription group compared with positive control group. [Conclusion]Tiaoganlipi prescription had an active effect on inhibiting of reversing of alcohol hepatic fibrosis in rats, and the correlativity of prescription with syndrome has pathological basis.